(Q43692331)

25 November 2017

title

Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis (English)

1 reference

25 November 2017

1 reference

Lee Mozessohn

1

1 reference

25 November 2017

Matthew C Cheung

2

1 reference

25 November 2017

Michael Crump

3

1 reference

25 November 2017

Rena Buckstein

4

1 reference

25 November 2017

Neil Berinstein

5

1 reference

25 November 2017

Kevin Imrie

6

1 reference

25 November 2017

John Kuruvilla

7

1 reference

25 November 2017

Eugenia Piliotis

8

1 reference

25 November 2017

Vishal Kukreti

9

1 reference

25 November 2017

language of work or name

1 reference

7 March 2014

1 reference

25 November 2017

1 reference

25 November 2017

volume

55

1 reference

25 November 2017

issue

11

1 reference

25 November 2017

page(s)

2502-2507

1 reference

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

Anti-CD20 antibody therapy for B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

The future of CD20 monoclonal antibody therapy in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

C-MYCtranslocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.885513

10.3109/10428194.2014.885513

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference